Cargando…

The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation

Chronic inflammatory diseases often affect women of childbearing age. Since biologic and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are more available, their use during conception, pregnancy and lactation has become a matter of concern. Current studies prove the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Góralczyk, Alicja, Kolossa, Katarzyna, Waszczak-Jeka, Marzena, Adamczak, Rafał, Jeka, Sławomir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2020
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394167/ https://www.ncbi.nlm.nih.gov/pubmed/32774212 http://dx.doi.org/10.5114/ada.2020.96294

Ejemplares similares

Assessment of the usefulness of skin autofluorescence as an indicator of disease activity and of the risk of developing diabetes in patients suffering from rheumatoid arthritis
por: Jeka, Sławomir, et al.
Publicado: (2015)

The rheumatoid hand in the light of fluorescence: a diagnostic technique of the future?
por: Żuchowski, Paweł, et al.
Publicado: (2019)

The changing role of ultrasonography examination in patients with rheumatoid arthritis in light of recent studies
por: Dura, Marta, et al.
Publicado: (2020)

The analysis of psychosomatic disorders in medical students in the context of their exposure to traumatic events
por: Kubiak, M., et al.
Publicado: (2023)

Efficacy of radiation synovectomy (radiosynovectomy or radiosynoviorthesis) with yttrium-90 in exudative inflammation of synovial membrane of knee joints in patients with rheumatic diseases – preliminary report
por: Zalewska, Joanna, et al.
Publicado: (2016)

Osteoporosis diagnostics in patients with rheumatoid arthritis
por: Węgierska, Małgorzata, et al.
Publicado: (2016)

Analysis of the emotional status of healthcare services in the context of the Covid 19 pandemic
por: Kubiak, M., et al.
Publicado: (2023)

Coexistence of rheumatoid arthritis and ankylosing spondylitis
por: Barczyńska, Tacjana Anna, et al.
Publicado: (2015)

Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis
por: Iwaszko, Milena, et al.
Publicado: (2018)

Addendum: Iwaszko et al., Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes 2018, 9, 64
por: Iwaszko, Milena, et al.
Publicado: (2018)

Th2 Cytokines (Interleukin-5 and -9) Polymorphism Affects the Response to Anti-TNF Treatment in Polish Patients with Ankylosing Spondylitis
por: Biały, Sylwia, et al.
Publicado: (2022)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis
por: Wielińska, Joanna, et al.
Publicado: (2021)

Polymorphisms within the RANK and RANKL Encoding Genes in Patients with Rheumatoid Arthritis: Association with Disease Progression and Effectiveness of the Biological Treatment
por: Wielińska, Joanna, et al.
Publicado: (2020)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the multicenter observational ACT-POL study
por: Stajszczyk, Marcin, et al.
Publicado: (2022)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review
por: Kingsley, Gabrielle H, et al.
Publicado: (2015)

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
por: Charles-Schoeman, Christina, et al.
Publicado: (2016)

Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Pharmacoeconomic evaluation of treatment effectiveness with selected biologic treatment in rheumatoid arthritis therapy
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients
por: Iwaszko, Milena, et al.
Publicado: (2021)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis
por: Iwaszko, Milena, et al.
Publicado: (2020)

Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
por: Baker, Matthew C., et al.
Publicado: (2023)

Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
por: Hsieh, Cho-Hsun, et al.
Publicado: (2022)

Are biologics more effective than classical disease-modifying antirheumatic drugs?
por: Nurmohamed, Michael T, et al.
Publicado: (2008)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy
por: Czekalska, Anna, et al.
Publicado: (2019)

The role of ultrasonography in monitoring long-standing rheumatoid arthritis: a pilot study
por: Jeka, Sławomir, et al.
Publicado: (2017)

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis
por: Plein, Sven, et al.
Publicado: (2020)

Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drugs
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
por: van Vollenhoven, Ronald, et al.
Publicado: (2018)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
por: Kaló, Zoltán, et al.
Publicado: (2017)

Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs
por: Abdul Razak, Salmi, et al.
Publicado: (2020)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
por: Frisell, Thomas, et al.
Publicado: (2023)

Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs
por: Murage, Mwangi J, et al.
Publicado: (2022)

Effects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis
por: Jung, Gyu-Un, et al.
Publicado: (2018)

Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine
por: Daïen, Claire I., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kc1mlg8vh47sfgbbnms2t50nn2